- Activity pressure is positive on the latest completed week.
ERMA
STO
Week ended 07 Aug 2026
Weekly Investor Report
Enorama Pharma AB (publ) · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
0.34 SEK
13.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -37.6% below the Trend Line and sits at 4.6% of its 52-week range. The latest completed week returned 13.0%, after a 32.9% four-week move. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
37
out of 100
Latest Close
0.34 SEK
7 Aug 2026
1W Return
13.0%
latest completed week
4W Return
32.9%
short-term follow-through
12W Return
18.5%
quarterly tape
Trend Breadth
23.1%
12 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
13.0%
Latest completed week; four-week move 32.9%.
Indicator stack
13/68
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
1 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -37.6% below the Trend Line and sits at 4.6% of its 52-week range. The latest completed week returned 13.0%, after a 32.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2012-week average 0.11
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 32.9% over four weeks, 18.5% over 12 weeks, and -88.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year12
Trend breadth23.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.77Latest activity-pressure read.
Pressure change57.6%Four-week change in activity pressure.
Leadership-79.25Latest relative-leadership reading.
RS change7.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 1 relevant articles.
0 positive · 1 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-88.7%Distance below the 52-week high.
13-week volatility20.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+56.3%Week of 22 May.
Worst week-33.4%Week of 13 Mar.
Latest week+13.0%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains3
Flat weeks0
Modest losses2
Sharp losses13
Recent vol20.7%13-week weekly-return volatility.
Base vol15.1%52-week weekly-return volatility.
Up/down split19/31Count of positive and negative weeks in the 52-week window.
Average skew10.7% / -11.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorSE Healthcare
4-week rank- / 100
Group average-1.1%
Trend breadth39.0%
Trend39.0%active weekly trend signals
MD42.0%positive activity pressure
RS21.0%positive relative leadership
Four-week leaders
IndustrySE Drug Manufacturers - Specialty & Generic
4-week rank1 / 19
Group average1.8%
Trend breadth15.8%
Trend15.8%active weekly trend signals
MD36.8%positive activity pressure
RS21.1%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape28/100
Trend, activity pressure, participation, and risk combine to a 28/100 tape read.
Indicator analysis31/100Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.
Activity pressure 0.20; No reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 1 relevant articles.
Enorama Pharma AB Revenue Breakdown – OMXSTO:ERMA Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 0.34 SEK | 13.0% | 0.54 SEK | 2.81 SEK | 0.77 | -79.25 | 96.3K | Off |
| 31 Jul 2026 | 0.30 SEK | -9.1% | 0.59 SEK | 2.83 SEK | 0.63 | -82.00 | 5.7K | Off |
| 24 Jul 2026 | 0.33 SEK | 26.9% | 0.65 SEK | 2.86 SEK | 0.57 | -80.67 | 88.5K | Off |
| 17 Jul 2026 | 0.26 SEK | 2.0% | 0.71 SEK | 2.88 SEK | 0.47 | -85.00 | 12.3K | Off |
| 10 Jul 2026 | 0.26 SEK | -13.9% | 0.78 SEK | 2.90 SEK | 0.49 | -85.87 | 55.1K | Off |
| 3 Jul 2026 | 0.30 SEK | 16.1% | 0.84 SEK | 2.92 SEK | 0.49 | -84.41 | 1.7K | Off |
| 26 Jun 2026 | 0.26 SEK | -23.9% | 0.91 SEK | 2.94 SEK | 0.44 | -86.57 | 61.6K | Off |
| 19 Jun 2026 | 0.34 SEK | -8.0% | 0.99 SEK | 2.97 SEK | 0.45 | -82.97 | 20.8K | Off |
| 12 Jun 2026 | 0.36 SEK | 7.4% | 1.07 SEK | 2.98 SEK | 0.48 | -81.58 | 21.5K | Off |
| 5 Jun 2026 | 0.34 SEK | -6.6% | 1.15 SEK | 3.00 SEK | 0.33 | -83.27 | 797 | Off |
| 29 May 2026 | 0.36 SEK | -18.8% | 1.23 SEK | 3.02 SEK | 0.12 | -82.66 | 239.6K | Off |
| 22 May 2026 | 0.45 SEK | 56.3% | 1.32 SEK | 3.04 SEK | -0.19 | -79.25 | 707.0K | Off |
| 15 May 2026 | 0.29 SEK | 7.9% | 1.39 SEK | 3.06 SEK | -0.65 | -86.63 | 25.5K | Off |
| 8 May 2026 | 0.27 SEK | -5.4% | 1.48 SEK | 3.08 SEK | -0.98 | -88.11 | 174.0K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.